SCHEMBL48434

SCHEMBL48434

Cn1c(N)nc(=O)c2[nH]cnc21

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.54
ADORA2B P29275 9/20 0.53
ADORA2A P29274 8/20 0.53
PDE4A P27815 7/20 0.53
PDE4B Q07343 7/20 0.53
PDE4C Q08493 7/20 0.53
PDE4D Q08499 7/20 0.53
ADORA3 P0DMS8 4/20 0.53
PIK3CD O00329 1/20 0.53
ALPL P05186 1/20 0.53
TMIGD3 P0DMS9 1/20 0.53
ADORA1 P30542 1/20 0.53
CYP2C19 P33261 1/20 0.53
HIF1A Q16665 1/20 0.53
PNP P00491 1/20 0.52
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
MAPT P10636 1/20 0.51
CFTR P13569 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29202432 0.79 PNP (0.50) ATAD2ADORA2BADORA2APDE4APDE4B
SCHEMBL28633086 0.79 PNP (0.52) ATAD2ADORA2BADORA2APDE4APDE4B
SCHEMBL16494563 0.79 PNP (0.52) ATAD2ADORA2BADORA2APDE4APDE4B
SCHEMBL6035390 0.78 PNP (0.63) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL29203684 0.78 PNP (0.49) ATAD2ADORA2BADORA2APDE4APDE4B
SCHEMBL31685640 0.78 ATAD2 (0.50) ATAD2ADORA2BADORA2APDE4APDE4B
SCHEMBL31685228 0.78 ATAD2 (0.50) ATAD2ADORA2BADORA2APDE4APDE4B
SCHEMBL563300 0.76 ADORA2B (0.63) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL21579656 0.75 ALDH1A1 (0.45) ATAD2ADORA2BADORA2APDE4APDE4B
SCHEMBL11304570 0.75 ATAD2 (0.54) ATAD2ADORA2BADORA2APDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 768 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098287-A1 METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS CHENG-YAO CHEN (TW) 2026-04-09 US claimed
EP-4569132-A2 METHOD, KIT AND SYSTEM FOR END LABELING OF NUCLEIC ACIDS Chen, Cheng-Yao (TW) 2025-06-18 EP claimed
CN-119948172-A Methods, kits and systems for nucleic acid end labeling 陈呈尧 2025-05-06 CN claimed
US-20250019744-A1 METHOD, KIT AND SYSTEM FOR END LABELING OF NUCLEIC ACIDS Chen, Cheng-Yao (TW) 2025-01-16 US claimed
US-20240385183-A1 METABOLIC AND MICROBIAL BIOMARKERS FOR DETECTION OF PANCREATICOBILIARY CANCERS NORTHWESTERN UNIVERSITY 2024-11-21 US claimed
WO-2024059788-A2 METHOD, KIT AND SYSTEM FOR END LABELING OF NUCLEIC ACIDS Chen cheng yao 2024-03-21 WO claimed
US-20240076707-A1 METHOD FOR MODIFYING DNA BY UTILIZING GLYCOSYLASE AND OXYAMINE COMPOUND NANJING UNIVERSITY (CN) 2024-03-07 US claimed
CN-117321218-A Regeneration method and kit of reusable initiators for nucleic acid synthesis 陈呈尧 2023-12-29 CN claimed
EP-4282871-A1 METHOD FOR MODIFYING DNA WITH GLYCOSIDASE AND OXYLAMINE COMPOUND Nanjing University (CN) 2023-11-29 EP claimed
CN-115367745-B Tungsten-containing substance hybridization and nitrogen-doped porous carbon material and preparation method thereof 北京化工大学 2023-11-24 CN claimed
EP-1419247-B1 METHOD FOR THE PRODUCTION OF NUCLEIC ACIDS CONSISTING OF STOCHASTICALLY COMBINED PARTS OF SOURCE NUCLEIC ACIDS DIREVO BIOTECH AG (DE) 2006-09-20 EP claimed
EP-1430145-A4 METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER YEDA RES & DEV (IL) 2006-08-16 EP claimed
US-20050130142-A1 Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids DIREVO BIOTECH AG (DE) 2005-06-16 US claimed
EP-1430145-A2 METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) 2004-06-23 EP claimed
US-20040096863-A1 Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2004-05-20 US claimed
EP-1419247-A2 METHOD FOR THE PRODUCTION OF NUCLEIC ACIDS CONSISTING OF STOCHASTICALLY COMBINED PARTS OF SOURCE NUCLEIC ACIDS Direvo Biotech AG (DE) 2004-05-19 EP claimed
WO-2003012100-A2 METHOD FOR THE PRODUCTION OF NUCLEIC ACIDS CONSISTING OF STOCHASTICALLY COMBINED PARTS OF SOURCE NUCLEIC ACIDS DIREVO BIOTECH AG (DE) 2003-02-13 WO claimed
EP-1281757-A1 Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids Direvo Biotech AG (DE) 2003-02-05 EP claimed
US-20030003454-A1 Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE 2003-01-02 US claimed
WO-2002076280-A2 METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2002-10-03 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098287-A1 METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS DNMT3L, ADAR, UNG ATAD2 352/4885ADORA2B 2037/4885ADORA2A 2649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.